Pharma BD Deal Intelligence
A buzzy-tech win: J&J paid $3.05 billion for Halda's RIPTAC platform and HLD-0915, whose Phase 1/2 data hit 59% PSA50 and 32% PSA90 in mCRPC, but PROTACs as a class still have zero approvals to their name.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →J&J sees value beyond lead prostate cancer program in $3B Halda takeout. While Halda's prostate cancer program clearly motivated the acquisition, J&J appears…
J&J's $3B Halda Acquisition Brings a Way to Overcome Drug Resistance in Prostate Cancer. Halda's innovative technology is designed to work even when cancers no…
J&J announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. for $3.05B in cash (Dec 29, 2025).
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Johnson & Johnson (NYSE: JNJ) completed its acquisition of Halda Therapeutics OpCo, Inc. on December 29, 2025 for $3.05 billion in cash, having announced the definitive agreement on November 17, 2025. The deal brings J&J Halda's proprietary RIPTAC (Regulated Induced Proximity TArgeting Chimera) platform for oral, targeted solid-tumor therapies and its lead asset HLD-0915, a once-daily oral RIPTAC in a Phase 1/2 trial for metastatic castration-resistant prostate cancer (mCRPC). First-in-human data reported in October 2025 showed HLD-0915 was well tolerated with encouraging anti-tumor activity — among 22 patients completing ≥2 cycles, 59% achieved a PSA50 response and 32% a PSA90 response, alongside ctDNA reductions. J&J expects to accelerate the ongoing Phase 1/2 study (primary completion targeted March 2027) and extend RIPTAC into additional solid tumors.
50K US cases/yr · $12.0B US Prostate Cancer Therapeutics Market
Metastatic castration-resistant prostate cancer (mCRPC) is the advanced stage of prostate cancer in which disease progresses despite androgen deprivation therapy (ADT) maintaining testosterone at castrate levels (<50 ng/dL). Prostate cancer is the second most common cancer in US men, with approximately 300,000 new diagnoses and 35,000 deaths annually; approximately 40,000-50,000 men are living with mCRPC at any time. Disease progression occurs through androgen receptor (AR) amplification, AR mutations (including AR-V7 splice variant), AR ligand-independent activation, and bypass pathways. Standard of care includes second-generation androgen receptor pathway inhibitors (abiraterone, enzalutamide, apalutamide, darolutamide), taxane chemotherapy (docetaxel, cabazitaxel), PARP inhibitors for HRR-mutant tumors (olaparib, rucaparib, niraparib, talazoparib), PSMA-targeted radioligand therapy (lutetium-177 PSMA-617/Pluvicto), and immunotherapy (sipuleucel-T/Provenge in limited setting). Despite this armamentarium, mCRPC remains universally lethal with median overall survival of 2-3 years, creating substantial need for novel mechanisms addressing AR-indifferent and treatment-refractory disease.
The mCRPC competitive landscape is dense across multiple mechanisms. Second-generation AR pathway inhibitors: Zytiga (abiraterone, J&J), Xtandi (enzalutamide, Pfizer/Astellas), Erleada (apalutamide, J&J), Nubeqa (darolutamide, Bayer). AR degraders: Arvinas/Pfizer's ARV-766 (luxdegalutamide) and bavdegalutamide (ARV-110), C4 Therapeutics, Foghorn. Novel AR-LBD inhibitors: Accutar's AC176, Kronos Bio. PSMA radioligand therapy: Pluvicto (lutetium-177 vipivotide tetraxetan, Novartis), with next-gen PSMA programs from Lantheus (PSMA-617), Point Biopharma (J&J, PNT2002), Telix (TLX591), Clarity (Cu-SAR-bisPSMA), Fusion (FPI-2265). PARP inhibitors for HRR-mutant: Lynparza (olaparib, AstraZeneca), Rubraca (rucaparib, Pharma&), Akeega (niraparib+abiraterone, J&J), Talzenna (talazoparib, Pfizer). CDK7 (Syros samuraciclib), AKT (capivasertib/Truqap, AstraZeneca), CYP11A1 (opevesostat, Merck), bispecifics (acapatamab PSMAxCD3, Amgen). Halda's HLD-0915 RIPTAC represents a novel class creating induced proximity between AR and an essential effector protein.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Halda Therapeutics, Inc. (this deal) | 2025 | $3.0B | — |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2025 deals · Johnson & Johnson deals · Oncology deals